Results 131 to 140 of about 92,020 (286)

Biochemical bone biomarkers in plasma cell dyscrasias

open access: yesBritish Journal of Haematology, EarlyView.
Visual abstract depicting that bone turnover markers reflect dynamic alterations in bone remodelling across the spectrum of plasma cell dyscrasias but remain limited by assay variability, biological confounding and incomplete integration with imaging and risk stratification.
Guido Nador   +4 more
wiley   +1 more source

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial

open access: yesBritish Journal of Haematology, EarlyView.
A subgroup analysis of efficacy, safety and QOL in patients who received selinexor in combination with bortezomib and dexamethasone (SVd) with and without selinexor dose reduction and who had lenalidomide‐refractory disease in the phase 3 BOSTON trial showed improvements in efficacy, quality of life (QOL) and safety outcomes with selinexor dose ...
Sosana Delimpasi   +8 more
wiley   +1 more source

Tp53 Genetic Mutations in Chronic Lymphocytic Leukemia Patients in Iraq

open access: yesJournal of Applied Hematology
Background: Chronic lymphocytic leukemia (CLL) is a malignant clonal proliferative condition of mature CD5+ B cells, with a 4.2/100,000 annual incidence rate and the median age at diagnosis is 72 years.
Kareem Abed Mobashr   +2 more
doaj   +1 more source

Diverging in Vivo Immune Response Patterns After Oral Food Challenge in Peanut Allergic Adults

open access: yesClinical &Experimental Allergy, EarlyView.
After the oral food challenge, peanut (PN)‐allergic adults were monitored over 4 weeks, which revealed diverging immune response patterns, with strong responders (SR) exhibiting heightened Ara h 2+ B cell expansion, PN sIgE induction and increasing PN‐specific Tconv. Weak responders (WR) had more activated PN‐specific Tregs.
Florent Fauchère   +7 more
wiley   +1 more source

Cytology‐First Diagnostic Workflow for Melanoma of Unknown Primary With Molecular Profiling

open access: yesCytopathology, EarlyView.
Cytology‑first diagnostic workflow for melanoma of unknown primary. Fine‑needle aspiration of an enlarged lymph node enables rapid cytologic evaluation and immunocytochemical confirmation of melanocytic lineage (SOX10). This early cytologic diagnosis facilitates timely surgical excision and comprehensive genomic profiling, supporting integrated ...
Hong Yu   +3 more
wiley   +1 more source

Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34+ progenitor cells during differentiation into antigen presenting cells [PDF]

open access: yes, 2001
The inducible costimulator receptor (ICOS) is a third member of the CD28 receptor family that regulates T cell activation and function. ICOS binds to a newly identified ligand on antigen presenting cells different from the CD152 ligands CD80 and CD86. We
Aicher, A   +9 more
core  

The Role of SAMHD1 in Viral Resistance and Transduction Efficiency Challenges in Pediatric Hematological Malignancies: Mechanistic Insights and Clinical Perspectives

open access: yesEuropean Journal of Haematology, EarlyView.
SAMHD1 regulates intracellular dNTP pools, influencing lentiviral transduction, gene therapy efficiency, and disease progression in pediatric hematological malignancies. Integrated bioinformatics and targeted strategies, including CRISPR and pharmacological inhibition, highlight its therapeutic potential.
Waseem Alzamzami
wiley   +1 more source

Immunophenotypic Characterization of Patients with Chronic Lymphocytic Leukemia by Flow Cytometry; Association with Disease Prognosis

open access: yesJournal of Mazandaran University of Medical Sciences, 2017
Background and purpose: Chronic lymphocytic leukemia (CLL) is characterized by clonal proliferation and accumulation of long-lived B lymphocytes within the peripheral blood, bone marrow, and secondary lymphoid organs.
Esmaeil Allahmoradi   +5 more
doaj  

Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Relapsed and refractory multiple myeloma (RRMM) remains associated with poor outcomes, particularly in patients exposed or refractory to proteasome inhibitors, immunomodulatory agents, and anti‐CD38 monoclonal antibodies. Targeting B‐cell maturation antigen (BCMA) has emerged as an effective therapeutic strategy, prompting the development of ...
Maria Eugenia Alvaro   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy